GAGodwin Abazho Aleku

Godwin Abazho Aleku

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Godwin Abazho Aleku has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis

    by Grace A. Okunlola, Godwin A. Aleku

    Chirality is an important determinant of drug action, as enantiomers can exhibit markedly different pharmacological and toxicological profiles. Although the importance of stereochemistry in drug efficacy is well established, its role in drug metabolism and disposition remains comparatively underexplored, despite the inherently stereoselective nature of drug metabolizing enzymes. Given the high prevalence of chiral drugs in clinical use and among newly approved drugs, a systematic evaluation of stereoselective drug metabolism is needed. Understanding stereoselective biotransformations has important implications for predicting drug disposition and response and may also inspire novel biocatalytic and biomimetic strategies to address challenges in enantioselective synthesis of chiral active pharmaceutical ingredients and their metabolites. In this Systematic Review, we examine current trends and practices in the investigation of stereoselectivity in drug metabolism, the key factors influencing stereoselective metabolism, and the associated challenges and opportunities. We highlight how biocatalytic approaches can improve stereoselective access to chiral metabolites, and how insights from drug metabolism and pharmacokinetics (DMPK) studies can inspire the development of novel biocatalytic and biomimetic synthesis routes. Transfer of learning and cross‑disciplinary collaboration between biocatalysis and DMPK scientists will be critical for accelerating progress in these areas and for addressing shared challenges, including stereoselectivity prediction.


  • Open Access

    Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis

    by Grace A. Okunlola, Godwin A. Aleku

    Chirality is an important determinant of drug action, as enantiomers can exhibit markedly different pharmacological and toxicological profiles. Although the importance of stereochemistry in drug efficacy is well established, its role in drug metabolism and disposition remains comparatively underexplored, despite the inherently stereoselective nature of drug metabolizing enzymes. Given the high prevalence of chiral drugs in clinical use and among newly approved drugs, a systematic evaluation of stereoselective drug metabolism is needed. Understanding stereoselective biotransformations has important implications for predicting drug disposition and response and may also inspire novel biocatalytic and biomimetic strategies to address challenges in enantioselective synthesis of chiral active pharmaceutical ingredients and their metabolites. In this Systematic Review, we examine current trends and practices in the investigation of stereoselectivity in drug metabolism, the key factors influencing stereoselective metabolism, and the associated challenges and opportunities. We highlight how biocatalytic approaches can improve stereoselective access to chiral metabolites, and how insights from drug metabolism and pharmacokinetics (DMPK) studies can inspire the development of novel biocatalytic and biomimetic synthesis routes. Transfer of learning and cross‑disciplinary collaboration between biocatalysis and DMPK scientists will be critical for accelerating progress in these areas and for addressing shared challenges, including stereoselectivity prediction.


  • Open Access

    Functional Mapping of Key Residues in Reductive Aminases Enabled by a High-Throughput RedAm Detect Assay

    by Jinming Xing, Georgie Orderley, Ruth T. Bradshaw Allen, Nabieha N. Ahmad, Camille Gourjault, Ardil Akgul, Sephia O. Alhassan, Nichapa Ngernanek, Siddhika Salke, Godwin A. Aleku

    Enzymatic reductive amination allows direct and stereoselective access to 1°, 2°, and 3° chiral amines under environmentally friendly reaction conditions. Enzyme discovery and engineering campaigns for this important transformation are crucial for industrial applications but currently rely on tedious and time-consuming screening of large libraries using expensive LC/LC-MS systems. Such engineering campaigns have also focused on optimizing a single aminase candidate per defined synthetic target. In this work, we have developed a versatile high-throughput (HTP) spectrophotometric/colorimetric RedAm detect assay for rapid and reliable quantitative monitoring of the aminase activity of recombinant aminase-expressing cells or unpurified cell extracts. The assay couples aminase product formation to an amine oxidase–HRP reporter system, yielding a colored dye/signal that can be monitored at 492/498 nm. We demonstrate its application to quantitatively monitor reductive amination reactions catalyzed by reductive aminases (RedAms), amine dehydrogenases (AmDHs), and amino acid dehydrogenases (AADHs). The RedAm detect assay enabled the HTP screening of 56 site saturation libraries in two RedAms, revealing 10 positions, including N113, D135, D188, Y196, W227, T234, Q257, A262, S270, and D297 in BacRedAm as important residues for RedAms’ catalytic function/substrate specificity. Extending our screening to four substrate combinations enabled the identification of positions R53, T115, Y154, L189, M195, Y196, W227, and Q257 in BacRedAm (and equivalent positions: R35, T99, Y139, L174, M180, Y181, W211, and Q241 in MaRedAm) that yielded mutants with improved activity of up to 7-fold compared to the wild-type enzyme in at least three of the four transformations. We propose that these residues act as potential “universal” hotspots for engineering substrate specificity in these enzymes across diverse substrates. Our work lays an important foundation for mapping sequence-activity relationships in RedAms at the enzyme family level to pave the way for more predictable, faster, and cost-effective engineering of RedAms for applications.


  • Open Access

    New Generation Modified Azole Antifungals against Multidrug-Resistant Candida auris

    by Yiyuan Chen, Yunxiao Li, Kazi S. Nahar, Mahbub Hasan, Caleb Marsh, Melanie Clifford, Godwin A. Aleku, Steven L. Kelly, David C. Lamb, Chengetai Diana Mpamhanga, et al.

    The rise of antifungal resistance and limited treatment options highlight the urgent need for new drug classes. Candida auris is a serious global health threat with few effective therapies. In this study, novel azole-based compounds were developed by modifying the azole core with cyclic heteroaliphatic linkers connecting aromatic and heteroaromatic rings. Several compounds showed potent activity against C. auris, including azole-resistant strains, with MICs ranging from 0.016 to 4 μg/mL. The compounds also demonstrated strong activity against C. albicans, Nakaseomyces glabratus, C. tropicalis, and C. parapsilosis, with MICs mostly below 1 μg/mL. Compounds 7, 18, and 21 were more potent than fluconazole. Compound 7 inhibited CYP51, eradicated C. auris biofilms, and showed better intracellular accumulation than fluconazole. In vivo studies in Galleria mellonella and Drosophila melanogaster confirmed efficacy at 5 mg/kg and no toxicity up to 50 mg/kg, supporting further development of this scaffold against multidrug-resistant C. auris infections.


  • Open Access

    Improved stereocontrol in reductive aminases through steric modification of residues around substrate and cofactor binding pockets

    by Jake Gooderham, Beatrice-Maria Zabava, David D. Aleku, Julie Vignot, Zuoye Xie, Ruth T. Bradshaw Allen, Mario Prejanò, Godwin A. Aleku

    Asymmetric reductive amination catalysed by reductive aminases (RedAms) provides a green and direct route to 2° and 3° chiral amines. Identifying residues or motifs in these enzymes that facilitate stereocontrol is essential for designing highly desirable enantiodivergent RedAm systems. In this work, we have identified key residues within both the cofactor and substrate binding pockets in a fungal reductive aminase (MaRedAm) and a bacterial imine reductase (AoIRED) that enable stereocontrol through steric modification. In MaRedAm, removing steric bulk at the cofactor binding pocket via W33A or R35A mutation improved (R)-selectivity towards the synthesis of (R)-rasagiline, achieving up to 95% enantiomeric excess (e.e.). Conversely, the W211A mutation at the substrate binding pocket of MaRedAm inverted the stereoselectivity, yielding (S)-rasagiline (42% e.e.). Likewise, varying steric bulk at position N241 in AoIRED allowed for enantiodivergency. Notably, modifying the N241 position significantly improved AoIRED's solution stability and storability. The wild-type enzyme typically precipitates out of solution within 8 h after purification, even when stored at 4 °C, whereas its N241H and N241Y variants remain in solution for up to >1 week. Molecular dynamics (MD) simulations provided detailed insights into the effect of steric modification on stereoselectivity at the cofactor and substrate binding pockets. MaRedAm W33A and W35A mutations induced reorganisation and downsizing of the active site, enhancing (R)-selectivity. In contrast, the W211A mutation enlarged the substrate binding pocket, increasing flexibility for substrate rotation. These findings contribute to the ongoing effort to establish the functional roles of key residues to allow efficient rational engineering of stereoselectivity in IREDs/RedAms.


  • Open Access

    Stereocontrol in Reductive Aminases through Steric Modification of Residues Around Substrate and Cofactor Binding Pockets

    by Jake Gooderham, Beatrice-Maria Zabava, David Aleku, Julie Vignot, Zuoye Xie, Ruth Bradshaw Allen, Mario Prejanò, Godwin Aleku

    Enzymatic reductive amination catalysed by imine reductases (IREDs) and reductive aminases (RedAms) provides green, stereoselective, and direct access to 2° and 3° chiral amines. Given existing interests in exploiting RedAms for commercial-scale synthesis of active pharmaceutical ingredients, developing efficient enantiodivergent RedAm systems would boost biocatalysis prospects in early drug discovery. To develop adaptable enantiodivergent RedAm systems, residues/motifs that can serve as handles for stereocontrol in this enzyme family need to be identified. In this work, we have identified residues at both the cofactor and substrate binding pockets in a fungal reductive aminase (MaRedAm) and a bacterial imine reductase (AoIRED) that allow stereocontrol through steric modification of the side chains. In MaRedAm, steric bulk removal as in W33A and R35A at the cofactor binding pocket improved (R)-selectivity towards the synthesis (R)-rasagiline with up to 95% e.e., whereas W211A mutation at the substrate binding pocket inverted the selectivity of MaRedAm to yield (S)-rasagiline (42% e.e.). Similarly, varying steric bulk at N241 in AoIRED achieved enantiodivergency as N241L/H/F/Y variants produce (S)-configured 1-methyl-1,2,3,4,-tetrahydroisoquinoline (92->99% e.e. compared to 85% e.e. (S) achieved by the wild-type), whereas N241A/S/C mutations yield the (R)-configured amine (up 40% e.e.). Atomistic insights obtained from molecular dynamics (MD) simulations revealed that steric modulation at the cofactor binding pocket (as in MaRedAM W33A and W35A) causes the reorganisation and downsizing of the active site. In contrast, the W211A mutation at the substrate binding pocket showed this pocket opening up to allow flexibility for the rotation of the substrate. Our work lays an important foundation for speedy rational engineering of stereoselectivity in IREDs/RedAms.

  • Top Cited Papers
    Open Access

    Imine Reductases and Reductive Aminases in Organic Synthesis

    by Godwin A. Aleku


  • Open Access

    Enzymatic N-Allylation of Primary and Secondary Amines Using Renewable Cinnamic Acids Enabled by Bacterial Reductive Aminases

    by Godwin A. Aleku, Gabriel R. Titchiner, George W. Roberts, Sasha R. Derrington, James R. Marshall, Florian Hollfelder, Nicholas J. Turner, David Leys

    Allylic amines are a versatile class of synthetic precursors of many valuable nitrogen-containing organic compounds, including pharmaceuticals. Enzymatic allylic amination methods provide a sustainable route to these compounds but are often restricted to allylic primary amines. We report a biocatalytic system for the reductive N-allylation of primary and secondary amines, using biomass-derivable cinnamic acids. The two-step one-pot system comprises an initial carboxylate reduction step catalyzed by a carboxylic acid reductase to generate the corresponding α,β-unsaturated aldehyde in situ. This is followed by reductive amination of the aldehyde catalyzed by a bacterial reductive aminase pIR23 or BacRedAm to yield the corresponding allylic amine. We exploited pIR23, a prototype bacterial reductive aminase, self-sufficient in catalyzing formal reductive amination of α,β-unsaturated aldehydes with various amines, generating a broad range of secondary and tertiary amines accessed in up to 94% conversion under mild reaction conditions. Analysis of products isolated from preparative reactions demonstrated that only selective hydrogenation of the C=N bond had occurred, preserving the adjacent alkene moiety. This process represents an environmentally benign and sustainable approach for the synthesis of secondary and tertiary allylic amine frameworks, using renewable allylating reagents and avoiding harsh reaction conditions. The selectivity of the system ensures that bis-allylation of the alkylamines and (over)reduction of the alkene moiety are avoided.


  • Prospects and Challenges of Developing Plant‐Derived Snake Antivenin Natural Products: A Focus on West Africa

    by Amina J. Yusuf, Godwin A. Aleku, Usman Rabiu Bello, Dahiru Umar Liman

    Snakebite envenomation (SBE) is an important public health issue that is now receiving renewed attention following its reclassification as a Neglected Tropical Disease (NTD). Most incidences occur in rural areas of resource‐limited countries, as such, timely and appropriate medical care for SBE is often inaccessible. The administration of anti‐snake venom serum (ASV) is the only effective definitive treatment of SBE, but treatment failure to available ASVs is not uncommon. Emerging evidence highlights the potential of small‐molecule compounds as inhibitors against toxins of snake venom. This presents an encouraging prospect to develop an alternative therapeutic option for the treatment SBE, that may be amenable for use at the point of care in resource‐constraint settings. In view of the pivotal role of natural products in modern drug discovery programmes, there is considerable interest in ethno‐pharmacological mining of medicinal plants and plant‐derived medicinal compounds toward developing novel snake venom‐neutralising therapeutics. In this review, we compile a collection of medicinal plants used in the treatment of SBE in West Africa and highlight their promise as potential botanical drugs or as sources of novel small‐molecule compounds for the treatment of SBE. The challenges that must be surmounted to bring this to fruition including the need for (sub) regional collaboration have been discussed.